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IT has been observed that when certain sulfonic acid dyes, such as trypan
blue, are injected into animals with tumors, the neoplasms become more highly
colored than the surrounding tissue. Unfortunately these dyes concentrate in
some vital organs to a much greater extent. An investigation by Moore, Tobin
and Aub (1943) of Br82 derivatives of Evans blue and trypan blue in tumor-
bearing mice showed that the tumor took up considerably more dye than the
surrounding tissue. The liver, however, took up about three times as much
radioactivity as the tumor. Stevens, Lee, Stewart, Quinlin and Gilson (1949)
studiedthedistribution ofradioactiveiodinatedtrypan blue, one ofthe compounds
first prepared by Bloch and Ray (1946). The concentration of radioactivity
in tumor tissue was several times greater than that in skeletal muscle or skin,
but considerably less than in the liver, spleen and kidneys.
The purpose of the present study was to deternine if such localization in
vital organs is a necessary concomitant to tumor localization by aromatic sulfonic
acids.
Because radioactivity offers a ready means of detection, the need of a colored
derivative no longer exists and sulfonic acids other than dyes may be employed.
Since certain derivatives of fluorene are known to produce tumors in various
sites in the animal body (Bielschowsky, 1944, 1947; Morris, Dubnik and Johnson,
1950; Wilson, DeEds and Cox, 1941), it is possible that other derivatives ofthis
molecule might be directed to tumors already present. The 2,7-disulfonic acid
of fluorene was selected and this compound was prepared labelled with S35.
Benzene sulfonic acid injected into dogs can be recovered unchanged in the
urine (Williams, 1947). Sammons, Shelswell and Williams (1941) report that
p-hydroxybenzenesulfonic acid is excreted unchanged from rabbits. It does not
even form an ethereal sulfate despite the fact that it possesses a phenolic hydroxy
group. Zehender (1943) found that the amino group of sulfanilic acid (p-amino-
benzenesulfonic acid) is acetylated to the extent of 75 per cent in the guinea-pig,
but that no cleavage ofthe sulfonic acid group from the ring occurs. A study of
various aminophenolsulfonic acids by Sammons, Shelswell and Williams (1941)
also indicates that these compounds are eliminated unchanged. It is, therefore,
apparent that aromatic sulfonic acids are stable compounds.
Since there is no evidence to indicate that the sulfonic acid groups offluorene-
2,7-disulfonic acid would be removed from the molecule, the distribution of
radioactivity following administration of the compound labelled with S35 shouldMARY F. ARGUS
be a direct measure ofthe distribution ofthe compoundin animaltissues. Results
accordingly are reported on this basis.
MATERIAL AND METHODS.
Preparation ofdisodiumfluorene-2,7-disulfonate-S35 (2,7-FDS35).
Fluorene, 5 g. (0.003 moles), together with concentrated H2SO4, 6-9 ml.
(0.12 moles), containing S35 (0.8 mc.), was warmed on a steam bath. After
half an hour the fluorene dissolved. The solution was warmed an additional
1 hours during which time a white precipitate formed. Most of the product
was dissolved by adding ice, and the solution was freed ofany undissolved residue
by filtering through a filter stick. The product was precipitated by the addition
of saturated aqueous NaCl solution. Two recrystallizations were carried out
by dissolving the product in a minimum of boiling water, filtering hot, adding
absolute ethanol untilslightly turbid and allowingthewhiteproduct to crystallize;
the yieldwas 95-42 per cent based on fluorene and 47-71 per cent based on H2S3504;
sulfur analysis gave 17-23 per cent S; the calculated value is 17-31 per cent S.
The p-toluidine salt melted at 326°; the melting point of the disulfonyl chloride
was 225-226°; Courtot and Geoffroy (1924) found 225-226O for fluorene-2,7-
disulfonyl chloride.
Animal studies.
Five to six-weeks-old Strain A (Bar Harbor) mice were employed as twenty-
third generation hosts for the subaxillary transplantation of a keratinizing
squamous cell carcinoma (Line A, stomach carcinomata originally obtained from
the Animal Supply and Research Units of the British Empire Cancer Campaign).
When the tumors were 10 days old, and weighed between 130-200 mg., each
mouse was administered, by tail vein injection, 0-25 ml. of saline solution con-
taining 5 0 mg. 2,7-FDS35 having a specific activity of 39,660 counts per minute
per mg. Base experiments in which the animals received twice this concentra-
tion of the compound failed to reveal any toxicity symptoms.
The animals were sacrificed at 2-, 8- and 32-hourintervals following treatment,
and pooled samples from 2 animals were used for each determination. The
mice were anesthetized with nembutal, and blood was removed by heart puncture
just prior to sacrifice. A 1-1 per cent solution of sodium oxalate (0 5 ml. to 1 ml.
blood) was used as an anticoagulant.
The tumor, liver, spleen, kidneys, stomach with contents and leg muscles
were removed, immediately weighed and suspended in a 1 per cent sodium
hydroxide solution containing 1 ml. of Tergitol per 250 ml. One ml. of this
solution was used for each 100 mg. tissue. The suspension was allowed to stand
48 hours at 5°. The mixture was then brought to room temperature and
thoroughly homogenized for 20 minutes. A 1 ml. portion was placed on a shallow
aluminium planchet and allowed to dry at room temperature. One ml. samples
of blood were plated directly on planchets.
Radioactivity measurements were made in an internal-type counter (Q-gas
chamber and Nuclear Instrument and Chemical Corporation Scaler, Unit Model
162) with an efficiency of 45 per cent. Each sample was counted for three
10-minute intervals and the net counts per minute above background recorded
for each sample.
274DISTRIBUTION OF RADIOACTIVITY 275
The concentration of 2,7-FDS35 in these samples was determined by direct
comparison with standard planchets prepared in the same manner and containing
known concentrations of the radioactive compound. Liver standards were used
for the liver, spleen and kidneys, muscle standards for the muscle and tumor,
and rabbit blood standards for the blood in order to eliminate correction for the
decay of S35, the standards were counted on the same day as the samples. The
total amount of 2,7-FDS35 present in the whole sample was determined by multi-
plying the concentration by the total weight of the sample. The total blood
volume was calculated on the basis of 63-2 ml. per kg. body weight (Oakley and
Warrack, 1940).
RESUILTS AND DISCUSSIONS.
The distribution of radioactivity in the organs and tissues of tumor-bearing
mice following injection of 2,7-FDS35 is given in Table I. Two hours after
administration the concentration of 2,7-FDS35 in the tumor (152 ,tg. per g. tissue)
was higher than in any organ. This concentration was four and one-third times
as great as that found in skeletal muscle and more than twice that in the spleen.
While comparatively substantial amounts of S35 were accounted for in the liver
and kidneys, these values were less than for the tumor tissue. The blood showed
a slightly higher concentration (164 jig. per ml.) than did the tumor.
TABLE I.-Distribution of Radioactivity in Tumor-bearing Micefollowing
Intravenous Injection of Disodium Fluorene-2,7-Disolfonate-S35
(5.0 mg. 2,7-FDS35 in 025 ml. saline).
Concentration
in pg.* per Total pg. Percentage
g. tissue or recovered. recovered.t
ml. blood.
Two hours:
Blood . . . . 164 . 331 . 3-31
Liver . . . . 130 . 295 . 2 95
Kidneys . . . 136 . 66 . 0 66
Spleen . . . 68 . 24 . 0-24
Stomach + contents . 143 . 67 . 0-67
Tumor . . . 152 . 58 . 0-58
Leg muscles . . 35
Eight hours:
Blood . . . . 79 . 174 . 1 74
Liver . . . . 50 . 108 . 1-08
Kidneys . . 62 . 35 . 0*35
Spleen . . . 30 . 11 . 0l11
Stomach + contents . 77 . 28 . 0-28
Tumor . . . 58 . 16 . 0-16
Leg muscles . . 52
Thirty-two hours:
Blood. . . . 2 . 4 . 0-04
Liver . . . . 7 . 11 . 011
Kidneys . . . 26 . 11 . 011
Spleen . . 5 . 1 . 001
Stomach + contents . 28 6 . 0-06
Tumor . . . 18 . 6 0-06
Leg muscles . . 00
* Calculated on the assumption that the S35 remains bound to the fluorene.
t The percentage recovery is based on the analysis of 2 mice (10 mg. 2,7-FDS35).MARY F. ARGUS
After 8 hours the localization of 2,7-FDS35 in the tumor was still greater than
in the liver, spleen or muscle, but slightly less than in the kidneys and blood.
The distribution studies after 32 hours reveal that none of this radioactive
compound remained in the muscle tissue. The concentration of 2,7-FDS35 in
the tumor was over three and one-half times that in the spleen and two and one-
half times that in the liver. The kidneys still showed a higher localization than
the tumor, but the concentration in the blood was now only one-ninth that in
the tumor. These ratios are given in Table II. Comparable ratios are also
given for 1131-labelled trypan blue as calculated from the data of Stevens, Lee,
Stewart, Quinlin and Gilson (1949).
TABLE II.-Ratios of the Concentration of Radioactivity in Tumor Tissue
to the Concentration in Other Tissuesfollowing a Single Injection
ofLabelled Compound to Tumor-bearing Mice.
2,7-FDS35 1131
trypan blue,
2 hrs. 32 hrs. 24 hrs.
Blood . . . 0 93 9°00
Liver . . . 117 2 57 . 0-15
Kidneys . . 112 0 69 . 0 34
Spleen . . . 2*24 3-60 . 0 38
Stomach. . . 106 0 64 . 0 87
Muscle . . . 4- 34 * * 3.33
* No radioactivity remained in the muscle tissue.
Contrasting the distribution of 2,7-FDS35 with that of 1131-labelled trypan
blue it is evident tht the fluorene derivative has not only maintained but has
bettered the ratio of concentrations in tumor and muscle tissue. This ratio is
4-34:1 for 2,7-FDS35 2 hours after injection. Stevens and associates report a
3-33:1 ratio for trypan blue at 24 hours. Thirty-two hours after injection of
2,7-FDS35 considerable radioactivity remained in thetumor while it was undetect-
able in the muscle.
One ofthe chief disadvantages in theuseof the dyes tested for tumor localiza-
tion studies is the fact that such vital organs as the liver, kidneys and spleen
take up large quantities of the dye. For example, with trypan blue six times
as much radioactivity was accounted for in the liver as in the tumor 24 hours
after injection. This ratio still persisted after 5 days when the final distribution
study was made (Stevens, Lee, Stewart, Quinlin and Gilson, 1949). With this
same compound the kidneys and spleen concentrated over three times as much
of the dye as did the tumor.
A much more favorable situation is found in the distribution of 2,7-FDS35.
At 8 and 32 hours only the kidneys had a slightly higher concentration of this
compound than did the tumor. At no time was the localization of the fluorene
derivative greater in the liver than in the tumor, and after 32 hours the con-
centration was two and one-half times greater in the tumor tissue than in the
liver. The spleen revealed a substantially lower localization of the S35-labelled
compound than did the tumor at all of the time intervals studied. This work
shows that localization in the liver and spleen does not necessarily exceed localiza-
tion of sulfonic acids in tumor tissue.
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The small percentages of radioactivity accounted for in the animal body
indicate that 2,7-FDS35 is readily excreted. This would be expected, since the
disulfonic acid groups impart a high degree of solubility to the fluorene molecule.
Such a fairly rapid excretion is a definite advantage over the high molecular
weight trypan blue which remains in the animal body after 5 days in concentra-
tions only slightly less than at 24 hours (Stevens, Lee, Stewart, Quinlin and
Gilson, 1949).
On the other hand the solubility of 2,7-FDS35 may be responsible for the
concentration of this compound in the kidneys. It is possible that the unfavor-
able ratio between kidney and tumor localization could be reversed if a slightly
less soluble compound were used. This would be worth while, however, only if
it could be accomplished without simultaneously increasing the conentration in
the liver.
Gastric secretion.-A noteworthy result was the high level of localization of
2,7-FDS35 in the stomach and its contents. In every case the concentration of
radioactivity in the stomach was comparable to or higher than that in the tumor.
Since the labelled compound was administered by intravenous injection, it is
probable that it was secreted by the stomach wall to reach the gastric contents.
Such secretion of a highly acid compound is not in agreement with the results
obtained in studies on the elimination of dyestuffs by the gastric glands. Ingra-
ham and Visscher (1935) investigated a large number of dyes, and found that the
only ones secreted by the stomach were those capable of acting as basic dyes.
Forty acid or amphoteric dyes studied were not eliminated by the gastric glands.
Following administration of 131-trypan blue, Stevens, Lee, Stewart, Quinlin
and Gilson (1949) foundradioactivity in the stomach in concentrations comparable
to that in tumor tissue, but much less than in the liver, kidneys and spleen.
While trypan blue is an acid dye by virtue of its sulfonic acid groups, it also
contains basic functional groups. Moreover, splitting of the azo linkage with
the formation of amino groups is known to take place in the animal body. The
radioactive iodine could have been directed to the stomach by a fragment of the
dye made more basic by this cleavage of the azo linkage. Another possibility
is that this radioactivity was due to the presence of the iodide ion formed by
removal of the iodine from the aromatic ring. It is well known that the iodide
ion is secreted in considerable amounts by the stomach. Unless it can be shown
that the 2,7-FDS35 reached the stomach by passage through the bile and regur-
gitation from the duodenum, it may be necessary to revise present ideas of the
secretory mechanism ofthe stomach.
SUMMARY.
A synthesis is described which incorporates radioactive sulfur (S35) into the
molecule of disodium fluorene-2,7-disulfonate. The distribution of radioactivity
in the tissues oftumor-bearing mice following a single injection of this compound
was studied at 2-, 8-, and 32-hour intervals. The ratios of concentration of
radioactivity in tumor tissue to the concentration in other tissues were deter-
mined. By comparison with similar ratios for 1131-labelled trypan blue, the
fluorene compound has increased the ratio of localization in tumor tissue com-
pared to liver, kidneys, spleen, blood and muscle. This investigation showed that
the localization of a sulfonic acid in the liver and spleen of tumor-bearing mice
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does not necessarily exceed the localization of this compound in the neoplastic
tissue.
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